US 11,992,477 B2
Pharmaceutical combination, composition, and combination preparation comprising glucokinase activator and SGLT-2 inhibitor and preparation methods and uses thereof
Li Chen, Shanghai (CN); Yongguo Li, Shanghai (CN); Gaosen Wang, Shanghai (CN); and Huisheng Gao, Shanghai (CN)
Assigned to HUA Medicine (Shanghai) Ltd., Shanghai (CN)
Appl. No. 17/058,883
Filed by HUA Medicine (Shanghai) Ltd., Shanghai (CN)
PCT Filed May 28, 2019, PCT No. PCT/CN2019/088863
§ 371(c)(1), (2) Date Nov. 25, 2020,
PCT Pub. No. WO2019/228364, PCT Pub. Date Dec. 5, 2019.
Claims priority of application No. 201810556685.6 (CN), filed on May 31, 2018.
Prior Publication US 2021/0214343 A1, Jul. 15, 2021
Int. Cl. A61K 31/4155 (2006.01); A61K 9/16 (2006.01); A61K 9/20 (2006.01); A61K 9/28 (2006.01); A61K 31/155 (2006.01); A61K 31/40 (2006.01); A61K 31/403 (2006.01); A61K 31/4035 (2006.01); A61K 31/4439 (2006.01); A61K 31/4985 (2006.01); A61K 31/522 (2006.01); A61K 31/7034 (2006.01); A61K 45/06 (2006.01); A61K 47/38 (2006.01); A61P 3/10 (2006.01); C07D 231/38 (2006.01); C07D 403/12 (2006.01)
CPC A61K 31/4155 (2013.01) [A61K 9/1611 (2013.01); A61K 9/1617 (2013.01); A61K 9/1635 (2013.01); A61K 9/1694 (2013.01); A61K 9/2009 (2013.01); A61K 9/2013 (2013.01); A61K 9/2027 (2013.01); A61K 9/2054 (2013.01); A61K 9/2086 (2013.01); A61K 9/2095 (2013.01); A61K 9/2813 (2013.01); A61K 9/284 (2013.01); A61K 9/2866 (2013.01); A61K 31/155 (2013.01); A61K 31/40 (2013.01); A61K 31/403 (2013.01); A61K 31/4035 (2013.01); A61K 31/4439 (2013.01); A61K 31/4985 (2013.01); A61K 31/522 (2013.01); A61K 31/7034 (2013.01); A61K 45/06 (2013.01); A61K 47/38 (2013.01); A61P 3/10 (2018.01); C07D 231/38 (2013.01); C07D 403/12 (2013.01)] 63 Claims
 
1. A fixed dose combination formulation, comprising:
(a) a glucokinase activator, which is a compound represented by the following formulae, or a pharmaceutically acceptable salt, an isotope labeled analogue, a crystalline form, a hydrate, a solvate, or a diastereomeric or enantiomeric form thereof,
 
 

OG Complex Work Unit Chemistry
 
 

OG Complex Work Unit Chemistry
 
 

OG Complex Work Unit Chemistry
 
 

OG Complex Work Unit Chemistry
 
(b) a SGLT-2 inhibitor; and
(c) one or more excipients.